ICAM1 and cancer: This view is further corroborated by animal studies that determined a 2.6-fold greater tumor volume in ICAM-1-deficient mice than in wild-type mice 14 days after injection of melanoma cells [50] or a development of malignant tumors in LFA-1-deficient but not wild-type mice injected with cancer cells [51].